Madrigal ‘encouraged’ by early launch progress of landmark NASH drug

Madri­gal Phar­ma­ceu­ti­cals is “mak­ing great progress” on the roll­out of its NASH drug Rezd­if­fra, ex­ec­u­tives said less than a month post-launch.

Rezd­if­fra was ap­proved in March as the first treat­ment for NASH, a de­bil­i­tat­ing liv­er dis­ease now al­so re­ferred to as meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis, or MASH. Madri­gal CEO Bill Si­bold told in­vestors on Tues­day that it’s too ear­ly to dis­close pre­scrip­tion da­ta, as the first ship­ments went out in April. But, he added, “What we’ve seen to date is re­al­ly en­cour­ag­ing.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.